XPHYF / XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

XPhyto Therapeutics Corp has announced that Dr Florian A. Sahr, a German-born and internationally-trained leader in drug formulation, technology trans more_horizontal

XPhyto Therapeutics Corp has updated on the progress of its Rotigotine transdermal (TDS) patch product candidate, which is a non-ergoline dopamine ag more_horizontal

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal